Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in New-onset Type 1 Diabetes
NCT02293837Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2015
- Primary completion
- Jul 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of tocilizumab in type 1 diabetes mellitus (T1D), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2015; status: completed.
02
Drugs
tocilizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02293837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293837.